Novo Nordisk (NVO), the maker of the blockbuster drug Ozempic, is cutting the price of its weight loss drug by more than half for even more patients that pay without insurance.

He and his team then compared the diagnoses for hair loss in these patients’ medical records and found that those prescribed semaglutide had a 50% higher risk of being diagnosed with a hair-loss condition compared to those prescribed Contrave. That risk was twice as high for women as for men.

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The restrictions began because the FDA declared a shortage of tirzepatide, often sold as Zepbound, and semaglutide, often sold as Wegovy, over.